Market/Novel Tech

Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients.  The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit. 

GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, has announced the results from the final analysis of the REALITY natural history study, which reaffirms the poor… Read More »GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit.